Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 13/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 13/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4924901 | 1.00 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4915569 | 0.88 | HDAC8 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4915575 | 0.88 | HDAC8 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4916706 | 0.88 | HDAC8 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4925767 | 0.86 | HDAC3 (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4925758 | 0.86 | HDAC3 (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL27703934 | 0.84 | HDAC8 (0.62) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4925847 | 0.84 | HDAC3 (0.62) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4925853 | 0.84 | HDAC3 (0.62) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4924034 | 0.81 | HDAC1 (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207694-A1 | Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them | ROSSI CRISTINA | 2008-08-28 | — | — | US | claimed |
| CN-101155780-A | Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them | MENARINI INT OPERATIONS LU SA (LU) | 2008-04-02 | — | — | CN | claimed |
| EP-1868997-A1 | HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | Menarini International Operations Luxembourg S.A. (LU) | 2007-12-26 | — | — | EP | claimed |
| WO-2006097460-A1 | HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2006-09-21 | — | — | WO | claimed |
| US-20080207694-A1 | Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them | ROSSI CRISTINA | 2008-08-28 | — | — | US | disclosed |
| CN-101155780-A | Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them | MENARINI INT OPERATIONS LU SA (LU) | 2008-04-02 | — | — | CN | disclosed |
| EP-1868997-A1 | HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | Menarini International Operations Luxembourg S.A. (LU) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006097460-A1 | HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207694-A1 | Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them | HDAC1, HDAC8, HDAC9 | HDAC3 8/4885HDAC4 9/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.